Director and 10% owner John E. Imhoff filed a Form 4 with the SEC on October 27, 2026, reporting the conversion of a convertible promissory note into 1,650,215 shares of Guided Therapeutics Inc common stock on September 30, 2026.

Key Highlights

  • Conversion amount: $115,515.07 was converted, consisting of $110,000 of principal and $5,515.07 of accrued interest under a September 25, 2025 Convertible Promissory Note.
  • Shares received: 1,650,215 shares of common stock were acquired at a conversion price of $0.07 per share.
  • Post-transaction ownership: Imhoff directly beneficially owns 22,902,888 shares of common stock following the reported transaction.
  • Note extinguished: According to the filing, "Following the conversion, the note has been paid in full."
  • Deferred installments included: By mutual agreement with the company, the converted amount included $60,000 of deferred installments due April through September 2026 and $50,000 of installments scheduled for October 2026 through February 2027.
  • Transaction code: The transaction was coded "C," indicating a conversion of a derivative security.

Imhoff Note Conversion Details at Guided Therapeutics

According to the Form 4 filed by John E. Imhoff, a director and 10% owner of Guided Therapeutics Inc (OTC:GTHP), Imhoff converted amounts outstanding under a Convertible Promissory Note originally dated September 25, 2025, into shares of the company's common stock. The conversion took place on September 30, 2026, at a conversion price of $0.07 per share, producing 1,650,215 newly acquired shares.

The filing discloses that the note was "convertible at the holder's election upon nonpayment of a scheduled monthly installment of $10,000 plus accrued interest, payable beginning November 30, 2025." The converted sum of $115,515.07 comprised $110,000 of principal and $5,515.07 of accrued interest. The filing further states that the conversion was made "by mutual agreement with the Company" and covered $60,000 in installments deferred from April through September 2026, as well as $50,000 in installments that had been scheduled for October 2026 through February 2027.

Following the transaction, the derivative security - the Convertible Promissory Note, which had carried an expiration date of February 28, 2027 and a conversion price of $0.07 - shows zero derivative securities remaining in Imhoff's beneficial ownership. His direct beneficial ownership of common stock following the conversion is reported as 22,902,888 shares.

What Was Disclosed

This Form 4 discloses director and 10% owner John E. Imhoff's September 30, 2026 conversion of $115,515.07 under a convertible promissory note into 1,650,215 shares of Guided Therapeutics common stock at $0.07 per share, leaving the note paid in full.